Skip to main content
Search form
Search
Subscribe to newsletter +
European Association of Hospital Pharmacists
Menu
Main menu
Home
About Us
Who we are
Board
Staff
Students
Transparency
Contact Information
Call for Expressions of Interest
Members
Associate membership
News
Press Releases
EAHP Newsletters
EAHP in the news
Multimedia Gallery
Events
Calendar
Academy
Synergy Masterclass
EAHP BOOST
Congresses
General Assemblies
Accreditations
EAHP Synergy Certification Courses
Open Learning
Get Involved
Sponsors and partners
HP Practice
EAHP COVID-19 Resource Centre
European Statements of Hospital Pharmacy
What hospital pharmacists do
EAHP-ESCP Oath to Society
FIP global statements
National legislation on hospital pharmacy
Good Practice Initiatives
Common training framework
Environmental Sustainability
European Council for Pharmacy Education Accreditation
Investigation of the hospital pharmacy profession in Europe
Hospital Pharmacy Day
SIGs
Controlled Substances Management
Special Interest Group on Investigation of medication errors and efficiency in oncology
Automated Medication Management
Working Towards Eliminating Avoidable Harm
Hazardous Medicinal Products
Hospital Pharmacist’s Preparedness for in-vivo gene therapy medicinal products
Investigation of Medication Errors in Intensive Care Units
Use of Prefilled Syringes in Intensive Care Units and Operating Theaters
Policy
Resources
Consultations
Position Papers
Get involved and keep up to date
Access to Medicines
Ageing society
Infectious Diseases and AMR
ATMPs
Bar coding medicines to the single unit
Biosimilar medicines
Clinical trials
Digital Health
EMA - EAHP collaboration
European List of Emergency Medicines
Falsified Medicines
Hazardous Medicinal Products
Hospital Pharmacy Specialisation
Medical device regulation
Medicines shortages
Patient safety
Pharmaceuticals in the environment
Pharmacy preparations and compounding
Procurement
Public spending austerity
SmPC
Vaccination
Workforce
Statements
GPIs
Publications
2019 EP Election Manifesto
General information
EAHP Annual report
European Journals of Hospital Pharmacy
EAHP Surveys of HP practice
EAHP History Book
Practical Pharmaceutics
Congress presentation webcasts
2024 European Parliament Election Manifesto
Member Center
You are here
Home
Section 5: Patient Safety and Quality Assurance
5PSQ-023
SAFETY AND TOLERABILITY OF VORICONAZOLE TREATMENT: A RETROSPECTIVE OBSERVATIONAL STUDY
5PSQ-022
DRUG-INDUCED APLASTIC ANAEMIA: AN ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)
5PSQ-021
EVALUATION OF THE PREVALENCE OF MULTI-RESISTANT BACTERIA IN THE INTENSIVE CARE UNIT AFTER SELECTIVE DECONTAMINATION OF THE GASTROINTESTINAL TRACT.
5PSQ-020
EVALUATION OF THE EFFICACY AND SAFETY OF EPCORITAMAB-BYSP IN PATIENTS WITH FOLLICULAR B LYMPHOMA: A CASE REPORT.
5PSQ-019
VALIDATION PRIOR TO THE DISPENSING OF MEDICINES AS A TOOL TO IMPROVE THE QUALITY OF THE PRESCRIPTION
5PSQ-018
ANALYSIS OF ERRORS IN THE MANUAL PREPARATION OF STERILE DRUGS FROM STOCK.
5PSQ-017
PHARMACEUTICAL INTERVENTIONS IN ORAL AND SUBCUTANEOUS MTX PRESCRIBING ERRORS
5PSQ-016
ASSESSMENT OF THE ACCREDITATION AND CONTINUOUS EDUCATION TESTS FOR PHARMACY TECHNICIANS WITHIN A CYTOTOXIC RECONSTITUTION UNIT
5PSQ-015
ANALYSIS OF THE OCCURRENCE OF ATRIAL FIBRILLATION WITH THE ADMINISTRATION OF IBRUTINIB: SHOULD WE BE CAREFUL WITH THIS DRUG?
5PSQ-014
ELECTRONIC COMMUNICATION OF THE DISCONTINUATION OF HOME TREATMENT PRESCRIBED TO PATIENTS IN A TERTIARY LEVEL HOSPITAL.
5PSQ-013
NEW METHOD FOR ASSESSMENT OF ENVIRONMENTAL VIRAL CONTAMINATION OF LIQUIDS PREPARED IN CLOSED-SYSTEM DRUG TRANSFER DEVICES
5PSQ-012
TOOLS OFFERED BY REGENERATIVE MEDICINE FOR THE TREATMENT OF OSTEOARTHRITIS – PLATELET RICH PLASMA (PRP).
5PSQ-011
TOXICITY OF IMMUNOTHERAPY TREATMENT IN CLINICAL PRACTICE
5PSQ-010
NATIONAL STANDARDISATION OF PRETERM PARENTERAL NUTRITION IN NEONATAL UNITS
5PSQ-009
OFF-LABEL USE OF INTRAVENOUS CYCLOPHOSPHAMIDE IN SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTING AS ACUTE LUPUS PNEUMONITIS: A CASE REPORT
Pages
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »
Follow Us